TransMedics Group, Inc. (TMDX) research
TransMedics Group, Inc.- Sector
- Health Care
- Last price
- $79.80
- As of
TransMedics Group, Inc. (TMDX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-10.
As of . Source: SEC EDGAR filings for TMDX. Method and limitations.
Share the TMDX intelligence card
See the full TMDX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TMDX on one page. Preview it with sample data, then open it live with a free account.
Preview the TMDX dossierActive signals for TMDX
- highCONSENSUS_BUY
8 tracked funds increased TMDX this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased TMDX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +2338% to TMDX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +153% to TMDX (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +4181% to TMDX (2026Q2)
FREE, NO ACCOUNT
Every signal on TMDX, as it fires
You are seeing 5 of 21 signals recorded on TMDX since 2026-05-26.
The five above landed across 2 days. The other 16 were recorded on 4 other days. 12 of the 21 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TMDX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 89377MAB5 · 2026Q2 | $72.9M | 0.05% | , |
| CITADEL ADVISORS LLCCUSIP 89377M109 · 2026Q2 | $37.1M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 89377MAB5 · 2026Q2 | $19.6M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 89377M109 · 2026Q2 | $16.5M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 89377M109 · 2026Q2 | $12.8M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 89377M109 · 2026Q2 | $594K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TMDX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TMDX against its peers
TMDX's operating margin of 17.9% ranks in the 85th percentile of 23 Health Care sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | TMDX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 605M USD | 1.4B USD | 13 | 25 |
| Gross margin | 59.9% | 59.0% | 53 | 19 |
| Operating margin | 17.9% | 6.2% | 85 | 23 |
| Net margin | 31.4% | 2.7% | 98 | 25 |
| Return on equity | 40.2% | 4.5% | 94 | 24 |
| P / E | 16.4x | 37.0x | 23 | 14 |
Peers (25): ATRC, AVAH, BKD, ACHC, PRVA, OPCH, CRVL, IRTC, NVST, WGS, MD, SEM, INSP, LIVN, ITGR, PGNY, LMAT, NVCR, XRAY, HAE, WAY, DOCS, ALHC, MMSI, ATEC. Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (TMDX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TMDX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TMDXand get the insider, 13F, options, and confluence read in one view.